Nuvalent (NUVL) Interest Coverage Ratio (2020 - 2026)
Nuvalent's (NUVL) quarterly Interest Coverage Ratio came in at 0.26 in Q1 2026, up 9.57% YoY from 0.23 in Q1 2025, and down 19.53% on a QoQ basis from 0.21 in Q4 2025.
Nuvalent (NUVL) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Interest Coverage Ratio data on file, last reported at 0.26 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 9.57% year-over-year to 0.26 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.94 (up 2.31% YoY) and the FY2025 annual result came in at 0.87, down 23.59% from the prior year.
- Interest Coverage Ratio retreated to 0.26 in Q1 2026, from 0.21 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.1 in Q4 2023 to a low of 59.0 in Q1 2023.
- A 5-year average of 13.51 and a median of 0.29 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio plunged 2833.23% — and 2024, when it surged 99.58%.
- Tracing NUVL's Interest Coverage Ratio over 5 years: stood at 21.78 in 2022, then soared by 99.53% to 0.1 in 2023, then plunged by 109.63% to 0.22 in 2024, then grew by 0.93% to 0.21 in 2025, then declined by 19.53% to 0.26 in 2026.
- The last three Interest Coverage Ratio figures came in at 0.26 (Q1 2026), 0.21 (Q4 2025), and 0.26 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.26 |
| Dec 31, 2025 | -0.21 |
| Sep 30, 2025 | -0.26 |
| Jun 30, 2025 | -0.29 |
| Mar 31, 2025 | -0.28 |
| Dec 31, 2024 | -0.22 |
| Sep 30, 2024 | -0.12 |
| Jun 30, 2024 | -0.15 |
| Mar 31, 2024 | -37.91 |
| Dec 31, 2023 | -0.10 |
| Sep 30, 2023 | -29.61 |
| Jun 30, 2023 | -22.16 |
| Mar 31, 2023 | -59.00 |
| Dec 31, 2022 | -21.78 |
| Sep 30, 2022 | -23.52 |
| Jun 30, 2022 | -16.53 |
| Mar 31, 2022 | -17.31 |
| Dec 31, 2021 | -0.74 |
| Dec 31, 2020 | -0.53 |